A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Interested in new trials?
Get alerts for new trials in your area by subscribing now
What is atopic dermatitis?
Atopic dermatitis is a chronic inflammatory skin disease that causes dry, intensely itchy, inflamed patches, often in skin folds, on the hands, and on the face, and it tends to flare and settle over time. It usually begins in childhood, about 13 percent of children have it compared with about 5 percent of adults, and it often travels with asthma, hay fever, and food allergy. It is not contagious. A weakened skin barrier and an overactive immune response both drive it, and genes, climate, and irritants play a role. Treatment starts with moisturizers and topical anti inflammatory creams; for moderate to severe disease there are biologic injections, starting with dupilumab in 2017, and oral JAK inhibitors. "Eczema" is a broader term, and atopic dermatitis is the type most trials study.
Atopic dermatitis often occurs with allergic asthma and food allergy. Other inflammatory skin conditions are on our psoriasis page.
Types of atopic dermatitis clinical trials
Biologic trials. New injections that block immune signals such as IL-13, IL-31, and OX40, some given every few months.
Oral drug trials. JAK inhibitors and other pills for moderate to severe disease, including in children.
Steroid free topical trials. Creams for mild to moderate disease that avoid the side effects of long term steroid use.
Pediatric trials. Studies in children and teenagers, who make up much of the patient population.
Allergy and atopic march studies. Research on how atopic dermatitis relates to food allergy and asthma.
Who can participate in atopic dermatitis clinical trials?
Most trials enroll people with moderate to severe atopic dermatitis that topical treatments have not controlled, measured by how much skin is affected and a severity score; some enroll mild disease for cream studies. Many specify an age range, often 12 and older, and require a break from current systemic treatments before starting. Eligibility always varies by study.
Severity of atopic dermatitis, and why it matters for trials
Mild. Small areas, controlled with moisturizers and creams; trials of new steroid free topicals.
Moderate. Larger areas or frequent flares despite creams; trials of creams, pills, and injections.
Severe. Widespread disease affecting sleep and daily life; most biologic and pill trials enroll here.
Do atopic dermatitis trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in an atopic dermatitis clinical trial
Identify your trial. Use the filters and match the stage or type and the treatment history named in study titles to your own.
Select your preferred location. Enter your city or state; large trials run at many sites, early phase studies at fewer centers.
Explore study details. Click "Learn More" for eligibility, prior treatment rules, and the visit schedule.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: how long you have had atopic dermatitis and how much skin is affected, the treatments you have tried, and other allergic conditions such as asthma.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.